Nitric oxide (NO) has been found to be important in many bodily systems, acting as a signaling molecule in the cardiovascular, nervous and immune systems, and being used by the nervous system as a neurotransmitter to regulate digestion, blood flow, memory and vision. Nitric oxide is released by macrophages (a type of white blood cell) to kill bacteria, viruses, fungi, parasites and tumor cells by disrupting their metabolism. Nitric oxide represents a potential wound therapeutic agent by means of its ability to regulate inflammation and tissue regeneration as well as eradicate microbial infections.

Nitric oxide is highly reactive and diffuses freely across membranes but has a half-life of only a few seconds. This combination of properties makes it an ideal signaling molecule both between adjacent cells and within a single cell.

As a result, it is widely acknowledged as having huge promise as a powerful weapon in the battle against multiple diseases. As scientific knowledge about nitric oxide has grown along with a deeper understanding of its pervasive nature across so many pathways, there has been a significant focus on nitric oxide in the pharmaceutical industry. Drugs which increase systemic levels of NO are the basis for anti-inflammatory drugs and vasodilators. Inhaled nitric oxide has become widely established – mainly used to treat pulmonary hypertension. Topical NO therapies – using a range of delivery methods – are under development for wound healing and dermatology.

And now, targeted therapy by our plasma-generation technology, IonoJet™.


Plasma medicine is an innovative and emerging field combining plasma physics, life sciences and clinical medicine to use high-energy plasma for therapeutic applications. It is the subject of advanced study at major academic institutions in the United States, Russia, Germany, Japan, the United Kingdom, France and Italy and has been studied over several decades for wound healing, dermatology, dentistry and oncology applications.

Since the plasma/NO stream generated by our IonoJet™ technology has been shown in investigations to generate NO activity up to 3 cm below the skin, we believe that the delivery of the NO via plasma energy allows the NO to pass through the skin and locally saturate the tissue and that this stimulates the NO pathways already present in the human body (47).


Our investigations led us to a technology that delivered therapeutic doses of nitric oxide with clinical success in wound-healing in Russia and Eastern Europe, winning the Russian Federation Prize for Science (13,14).

We secured an option to acquire the US patent for the technology in 2011, and in 2014 raised funds from institutions in the United Kingdom that enabled us to exercise this option, acquire and improve the technology for ourselves and embark on our regulatory strategy.

Our IonoJet™ prototype device has been significantly re-engineered and updated from that of its predecessor with higher performance metrics in order to produce a reliable and consistent plasma/NO stream and to address regulatory requirements and expectations.

CAUTION – The IonoJet™ is an Investigational Device limited by Federal (or United States) Law to investigational use.